Sapience Therapeutics
Biotechnology, Tarrytown, New York, United States, 11-50 Employees
Phone Number: 19*********
Who is SAPIENCE THERAPEUTICS
At Sapience, we think boldly about the possibilities for treating cancer. We aim to discover and develop peptide therapeutics to address oncogenic and immunogenic dysregulation that drive...
Read More
-
Headquarters: Tarrytown, New York, United States
-
Date Founded: 2015
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Barry Kappel
Email
Phone
Industry: Biotechnology
SIC Code: 5122
Does something look wrong? Fix it. | View contact records from SAPIENCE THERAPEUTICS
Sapience Therapeutics Org Chart and Mapping
Jim Rotolo
SVP of Translational Pharmacology, Head of Research at Sapience Therapeutics, Inc.
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Sapience Therapeutics
Answer: Sapience Therapeutics's headquarters are located at Tarrytown, New York, United States
Answer: Sapience Therapeutics's phone number is 19*********
Answer: Sapience Therapeutics's official website is https://sapiencetherapeutics.com
Answer: Sapience Therapeutics's revenue is $5 Million to $10 Million
Answer: Sapience Therapeutics's SIC: 5122
Answer: Sapience Therapeutics has 11-50 employees
Answer: Sapience Therapeutics is in Biotechnology
Answer: Sapience Therapeutics contact info: Phone number: 19********* Website: https://sapiencetherapeutics.com
Answer: At Sapience, we think boldly about the possibilities for treating cancer. We aim to discover and develop peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Our pipeline of SPEARsTM (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. We are advancing our lead programs, ST316, a first-in-class antagonist of -catenin, and ST101, a first-in-class antagonist of C/EBP, through Phase 1-2 clinical trials. Please engage with us on this platform to learn more!
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month